Search Results
Active Filters
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Apr 28, 2025, 17:31 ET Novartis' VANRAFIA Approval Disrupts IgA Nephropathy Market, Paving Way for New Therapeutic Paradigm | DelveInsight
New Medicine for IgA Nephropathy Povetacicept (ALPN-303) is a dual inhibitor targeting B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL)—two critical cytokines involved in the
More news about: DelveInsight Business Research, LLP